Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Prior Antibiotic Exposure May Hinder Checkpoint Inhibitor Efficacy

Publish date:: April 9, 2019

Key clinical point: Prior antibiotic exposure may hinder the efficacy of checkpoint inhibitors.

Major finding: Median overall survival was 2 months with prior antibiotic exposure versus 26 months without.

Study details: A prospective, observational study of 196 patients with various cancers treated with immune checkpoint inhibitors.

Disclosures: The study was internally supported. Dr. Pinato reported receiving grant funding from Merck and Bristol-Myers Squibb unrelated to the study, as well as honoraria from ViiV Healthcare.

Citation:

Pinato DJ et al. ASCO-SITC, Abstract 147.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Head & Neck/Thyroid Cancers

Immunotherapy could fill unmet need in leptomeningeal metastases,

New cancer drugs may have saved more than 1.2 million Americans,

‘Tour de force’ study reveals therapeutic targets in 38% of cancer patients,

Survey quantifies COVID-19’s impact on oncology,

VTE, sepsis risk increased among COVID-19 patients with cancer,